Day: June 2, 2025

Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published:On January 9, 2025 in a press release titled “Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment” On January 23, 2025 in a press release titled “Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the TD Cowen 9th Annual Future of the Consumer Conference on Wednesday, June 4, 2025, at 3:30 p.m. EST. A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes...

Media Release COPENHAGEN, Denmark; June 2, 2025New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trialGenmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months,...

Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport’s executive team on the Company’s strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event’s agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone’s Comprehensive Epilepsy Center,...

On Monday 2.6.2025 Kvika announced that post week 22 buy-back Kvika held 157,410,410 of own shares which corresponds to 2.902% of issued shares. However, 157,410,410 of own shares corresponds to 3.34% of issued shares. The revised announcement is as follows: In week 22 Kvika banki hf. („Kvika“ or „the bank“) purchased 23,000,000 of its own shares at the purchase price ISK 380,150,000. See further details below:Date Time No. of shares purchased Share price (rate) Purchase price26.5.2025 10:12:07 1,500,000 15.800 23,700,00026.5.2025 10:53:38 1,000,000 15.925 15,925,00026.5.2025 11:11:52 1,000,000 15.875 15,875,00026.5.2025 13:15:32 1,500,000 15.800 23,700,00026.5.2025 14:17:22 1,000,000 15.800 15,800,00026.5.2025 15:19:12 750,000 15.800 11,850,00027.5.2025 10:18:08 2,000,000 15.975 31,950,00027.5.2025 11:02:06 1,000,000 15.975 15,975,00027.5.2025 12:31:33 1,000,000 15.950 15,950,00027.5.2025 14:09:45 1,500,000 15.900 23,850,00027.5.2025 15:04:50 1,250,000 15.900 19,875,00028.5.2025 10:33:34 2,000,000 17.000 34,000,00028.5.2025 13:21:20 2,000,000 17.350 34,700,00028.5.2025 14:17:08 1,000,000 17.400 17,400,00030.5.2025 10:50:38 2,000,000 17.750 35,500,00030.5.2025 12:10:15 1,500,000 17.700 26,550,00030.5.2025 14:54:22 1,000,000 17.550 17,550,000Total   23,000,000   380,150,000The...

Attached please find Company Announcement no 6 – 2025AttachmentCompany Announcement no 6 – 2025

Evo Series Expands with Options for Increased Material and Color Expression and User Comfort Chicago, IL., June 02, 2025 (GLOBE NEWSWIRE) — Workplace solutions leader Allsteel has expanded its best-selling Evo series with a more sustainable seating option, designed for everyone, everywhere. Evo’s new enhancements allow the chair to meet the ever-changing demands of modern workspaces while pushing the boundaries of versatility, sustainability, and human-centered design. Now offering options for an eco-friendly Quilted Knit Back made from SEAQUAL® upcycled marine litter as well as carbon neutral models, the upgraded Evo collection not only enhances the overall chair’s design but adds a layer of sustainability that align with Allsteel’s core principles.  Evo breaks ground with its new sustainable back. In collaboration with Camira...